The U.S. Food and Drug Administration (FDA) has approved a treatment regimen using Danish pharmaceutical company Genmab's Epkinly (epcoritamab-bysp) in combination with rituximab and lenalidomide for patients with relapsed or refractory follicular lymphoma. The approval was announced in a press release.
The decision is based on results from the phase 3 Epcore FL-1 study.
Follicular lymphoma is typically a slow-growing form of non-Hodgkin lymphoma (NHL), affecting approximately 15,000 new patients each year in the United States. The disease is currently considered incurable with existing standard treatments.
